Practice Management News

A number of commonly used medications can promote weight gain in patients, but there are more weight-favorable alternatives that physicians can help patients transition to.

Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.

In this video, Lyons Hardy, MS, RN, P-MHNP, clinical assistant professor and concentration lead of the psychiatric mental health nurse practitioner program at Virginia Commonwealth University School of Nursing, discussed key takeaways she brought home from the American Psychiatric Nurses Association Annual Conference.

Inpatient and outpatient volume increased for pediatric patients with an eating disorder following the onset of the COVID-19 pandemic, according to a study published in JAMA Pediatrics.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

So, you’ve reached consensus with your partners that it’s time to sell the practice. You’ve done your research on potential platforms/buyers, and you’ve started to engage advisers. What’s next? Time to look inward.

Teva Pharmaceuticals announced it recently completed resubmission of a new drug application to the FDA for mdc-IRM, a risperidone subcutaneous long-acting injectable for the treatment of schizophrenia.

CHICAGO — A history of two or more head injuries was associated with mild behavioral impairment in older adults, according to a poster presentation at the 2022 American Neurological Association annual meeting.

In this video, Lyons Hardy, MS, RN, P-MHNP, clinical assistant professor and concentration lead of the psychiatric mental health nurse practitioner program at Virginia Commonwealth University School of Nursing, discussed a presentation she gave with a colleague at the American Psychiatric Nurses Association Annual Conference.

Biomind Labs Inc. has announced positive initial results from the first part of its phase 2 trial of a novel liquid inhaled formulation of N,N-Dimethyltryptamine, or DMT, for treatment-resistant depression.